Biotech IV Monitor

CELC — Celcuity Inc.

$4.0B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Celcuity Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2028.

Next readoutJanuary 2028in ~14 months
Upcoming readouts21 Phase 3
Market cap$4.0B
Cash & investments$643M~9 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 1/2 Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male · NCT06190899
January 2028
Recruiting
Phase 3 Arm A: Gedatolisib + Palbociclib + Fulvestrant
Breast Cancer · NCT06757634
March 2029
Recruiting

Cash position

Celcuity Inc. reported $643M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $73M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow CELC, you can start the conversation.
Track CELC in real time
See live implied volatility for CELC and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on CELC
Contact — questions or corrections about CELC: dukeupt@gmail.com